Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum.
Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum.
复制标题
DOI：
10.1186/1471-2407-14-448
复制
发表时间：
2014-06-18
期刊：
影响因子：
3.8
通讯作者：
Stopka T
中科院分区：
文献类型：
--
作者：
Sochor M;Basova P;Pesta M;Dusilkova N;Bartos J;Burda P;Pospisil V;Stopka T
microRNA（miRs）是一类独特的基因表达转录后调节因子，在血清中具有显著的稳定性。几种miR是致癌的（oncomiR），并且在乳腺癌的发病机制中失调，并具有抑制肿瘤抑制因子的功能。对这些循环肿瘤衍生产物的常规血液监测可能对早期乳腺癌（EBC）患者的诊断和复发检测有显著益处。本项目的目的是确定63名EBC患者和21名健康对照血清中miR-155、miR-19 a、miR-181 b、miR-24相对于let-7a的表达。进行纵向多变量数据分析以随机建模疾病阶段期间每种oncomiR的血清水平：从诊断开始、手术后和化疗/放疗后。此外，该分析用于评价使用当前临床预后因素（包括HER 2、Ki-67和III级）亚组的EBC患者中的oncomiR水平。EBC患者在诊断时显著过表达oncomiR。手术切除后，miR-155、miR-181 b和miR-24的血清水平显著降低（分别为p = 1.89e-05、5.41e-06和0.00638），而miR-19 a在治疗后显著降低（p = 0.00869）。此外，在高风险患者的情况下，与低风险组相比，miR-155、miR-19 a、miR-181 b和miR-24的血清水平显著更丰富（p = 0.026、0.02567、0.0250和0.00990），并且在治疗后显示出下降趋势。与诊断时的对照组相比，EBC患者血清中的OncomiR含量明显更丰富。还观察到反映EBC风险的oncomiR水平的差异。测试oncomiR可用于诊断目的，并且还可能用于EBC的随访研究中的复发检测。
MicroRNAs (miRs) represent a distinct class of posttranscriptional modulators of gene expression with remarkable stability in sera. Several miRs are oncogenic (oncomiRs) and are deregulated in the pathogenesis of breast cancer and function to inhibit tumor suppressors. Routine blood monitoring of these circulating tumor-derived products could be of significant benefit to the diagnosis and relapse detection of early-stage breast cancer (EBC) patients. Aim of this project was to determine expression of miR-155, miR-19a, miR-181b, miR-24, relative to let-7a in sera of 63 patients with EBC and 21 healthy controls. Longitudinal multivariate data analysis was performed to stochastically model the serum levels of each of the oncomiRs during disease phases: from diagnosis, after surgery, and following chemo/radiotherapy. Moreover, this analysis was utilized to evaluate oncomiR levels in EBC patients subgrouped using current clinical prognostic factors including HER2, Ki-67, and grade III. EBC patients significantly over-express the oncomiRs at the time of diagnosis. Following surgical resection the serum levels of miR-155, miR-181b, and miR-24 significantly decreased (p = 1.89e-05, 5.41e-06, and 0.00638, respectively) whereas the miR-19a decreased significantly after the therapy (p = 0.00869). Furthermore, in case of high-risk patients serum levels of miR-155, miR-19a, miR-181b, and miR-24 are significantly more abundant in comparison to low-risk group (p = 0.026, 0.02567, 0.0250, and 0.00990) and show a decreasing trend upon therapy. OncomiRs are significantly more abundant in the sera of EBC patients compared to controls at diagnosis. Differences in oncomiR levels reflecting EBC risk were also observed. Testing the oncomiRs may be useful for diagnostic purpose and possibly also for relapse detection in follow-up studies of EBC.
登录
查看更多内容
影响因子：
8
作者：
Kim, K.;Chadalapaka, G.;Lee, S-O;Yamada, D.;Sastre-Garau, X.;Defossez, P-A;Park, Y-Y;Lee, J-S;Safe, S.
通讯作者：
Safe, S.
用于乳腺癌检测的血清全基因组 microRNA 分析
影响因子：
5
作者：
Wu, Qian;Wang, Chao;Ge, Qinyu
通讯作者：
Ge, Qinyu
影响因子：
9.3
作者：
Eichelser, Corinna;Flesch-Janys, Dieter;Schwarzenbach, Heidi
通讯作者：
Schwarzenbach, Heidi
DOI：
10.1186/bcr3446
发表时间：
2013
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Schwarzenbach H
通讯作者：
Schwarzenbach H
DOI：
10.4161/cc.24757
发表时间：
2013-06-01
期刊：
Cell cycle (Georgetown, Tex.)
影响因子：
--
作者：
Bisso A;Faleschini M;Zampa F;Capaci V;De Santa J;Santarpia L;Piazza S;Cappelletti V;Daidone M;Agami R;Del Sal G
通讯作者：
Del Sal G